X
[{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"MaaT Pharma","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"Undisclosed","newsHeadline":"MaaT Pharma Announces \u20ac18 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"Enterome","pharmaFlowCategory":"D","amount":"$52.6 Million","upfrontCash":"Undisclosed","newsHeadline":"Enterome Completes \u20ac46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Symbiosis, AstraZeneca Sign Supply Agreement for Sterile Vaccine Manufacture","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Symbiosis Pharmaceutical Services LTD
Filters
Companies By Therapeutic Area
Details:
Financing will be used to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.
Lead Product(s):
EO2401
Therapeutic Area: Oncology
Product Name: EO2401
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Recipient:
Enterome
Deal Size: $52.6 Million
Upfront Cash: Undisclosed
Deal Type: Financing
June 25, 2020
Details:
Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.
Lead Product(s):
AZD1222
Therapeutic Area: Infections and Infectious Diseases
Product Name: AZD1222
Highest Development Status: Phase II/ Phase III
Product Type: Vaccine
Partner/Sponsor/Collaborator:
AstraZeneca
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
June 22, 2020
Details:
The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.
Lead Product(s):
MaaT013
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Large molecule
Recipient:
MaaT Pharma
Deal Size: $19.5 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
February 05, 2020